A randomised phase II study evaluating vismodegib as neoadjuvant treatment of basal cell carcinoma preceding Mohs micrographic surgery: results and lessons learned

Abstract

Vismodegib is indicated for adults with metastatic or locally advanced basal cell carcinoma (BCC) inappropriate for surgery or radiotherapy. Neoadjuvant vismodegib has been reported to shrink locally advanced and high‐risk BCC before surgery. It is unclear whether non‐contiguous residual tumour remains after neoadjuvant treatment.

This article is protected by copyright. All rights reserved.

http://bit.ly/2SHU2DX